Review article: Quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 2, 1996, Pages 123-132

  Weldon, M J ^a   Lowe, C ^a   Joseph, A E A ^a   Maxwell, J D ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; DIAGNOSTIC AGENT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM; OXIME; TECHNETIUM COMPLEX; ALPHA 1 ANTITRYPSIN; INDIUM 111; TECHNETIUM 99M;

CROHN DISEASE; HOSPITALIZATION; HUMAN; LEUKOCYTE; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULCERATIVE COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; ENDOSCOPY; ENTERITIS; ISOTOPE LABELING; PRIORITY JOURNAL; QUESTIONNAIRE; T LYMPHOCYTE;

ACUTE-PHASE PROTEINS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INDIUM RADIOISOTOPES; LEUKOCYTES; ORGANOTECHNETIUM COMPOUNDS; OXIMES; SEVERITY OF ILLNESS INDEX; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0029869589     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.728120000.x     Document Type: Review

References (70)

1. Weldon MJ, Maxwell JD. Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? Gut 1994; 35: 867-71.
2. Maratka Z. Crohn's disease activity indices: need for distinguishing activity from severity. Hepatogastroenterology 1981; 28: 187-8.
3. Best W, Becktel J, Singleton J, et al. Development of a Crohn's disease activity index. National Co-operative Crohn's disease study. Gastroenterology 1976; 70: 439-44.
4. Hodgson HJF. Assessment of drug therapy in inflammatory bowel disease. Br J Clin Pharmacol 1982; 14: 159-70.
5. Beck IT. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci 1987; 32: 265-415. (Review.)
6. De Dombal FT, Softley A. IOIBD report no. 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987; 28: 474-81.
7. Andre C, Descos L, Landias P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571-4.
8. Harvey R, Bradshaw J. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
9. Vim Hees P, Van Elteren P, Van Lier H, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279-86.
10. Prantera C, Baiocchi G, Levenstein S, et al. Clinical and laboratory parameters in Crohn's disease: relation to disease activity, morphology and extent. Ital J Gastroenterol 1981; 13: 24-7.
11. Singleton JW. Laboratory investigations and disease activity in inflammatory bowel disease. In: Allan RN, Keighley MRB, Alexander-Williams J, Hawkins C, eds. Inflammatory Bowel Disease, Edinburgh: Churchill Livingstone, 1990: 199-206.
12. Wright JP, Marks IN, Parfitt A. Simple clinical index of Crohn's disease activity. South Afr Med J 1986; 68: 502.
13. Camilleri M, Proano M. Advances in the assessment of disease activity in inflammatory bowel disease. Mayo Clin Proc 1989: 64: 800-7. (Review.)
14. Pallone F, Ricci R, Boirivant M, et al. Measuring the "activity" of Crohn's disease. Ital J Gastroenterol 1981; 13: 51-3.
15. Truelove S, Witts L. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 2: 1041-4.
16. Truelove S, Witts L. Cortisone and corticotrophin in ulcerative colitis. BMJ 1960; 1: 464-7.
17. Jewell DP, Caprilli R, Mortensen N, et al. Indications and timing of surgery in severe ulcerative colitis. Gastroenterol Int 1991; 4: 161-4.
18. Powell-Tuck J, Brown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-7.
19. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-74.
20. Walmsley RS, Ayres R, Allan RN. A really useful simple colitis activity index. Gut 1994; 35: S29.
21. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
22. Drossman DA, Leserman J, Mitchell CM, et al. Health status and health care use in persons with inflammatory bowel disease. A national sample. Dig Dis Sci 1991; 36: 1746-55.
23. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
24. Floren CH, Benoni C, Willen R. Histological and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-62.
25. Hanauer SB. Guidelines for the clinical evaluation of drugs for patients with inflammatory bowel disease. Fed Register 1991; 56: 519.
26. Modigliani R, Mary Y-J. Groupe d'études therapeutiques des affections inflammatoires digestives. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990; 98: 811-8.
27. Shove DC, Morson BC. Management of Crohn's disease. In: Weterman IT, Pena AS, Booth CC, eds. Proceedings of the Workshop on Crohn's Disease, Leiden. Amsterdam: Exerpta Medica, 1976: 20-3.
28. Jenkins D, Goodall A, Drew, K, et al. What is colitis? Statistical approach to distinguishing clinically important change on rectal biopsy specimens. J Clin Path 1988; 41: 72-9.
29. Binder V. Cell density in lamina propria of the colon: a quantitative method applied to normal subjects and ulcerative colitis patients. Scand J Gastroenterol 1970; 5: 485-90.
30. Morston BC. Rectal and colonic biopsy in IBD. Am J Gastroenterol 1977; 67: 417-26.
31. Saverymuttu S, Peters A, Hodgson H, et al. Indium-111 autologous leucocyte scanning: comparison with radiology for imaging the colon in inflammatory bowel disease. BMJ 1982; 285: 255-7.
32. Morson B. Rectal biopsy in inflammatory bowel disease. N Engl J Med 1972; 287: 1337-9.
33. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
34. Aronsen KF, Ekelund G, Kindmark CO, et al. Sequential changes of plasma proteins after surgical trauma. Scand J Clin Lab 1972; 29: 127-36.
35. Pagan E, Dyck R, Maton P, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351-9.
36. Cooke W, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol 1984; 1984: 17-25.
37. Andre C, Descos L, Vignal J. C-reactive protein level predicts Crohn's disease relapse in quiescent patients. Gut 1979; 20: A940.
38. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401-5.
39. Cooke W, Fowler D, Cox E, et al. The clinical significance of seromucoids in regional ileitis and ulcerative colitis. Gastroenterology 1958; 34: 910-19.
40. Gomes P, Du BC, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-5.
41. Calvin J, Neale G, Fotherby K, et al. The relative merits of acute phase proteins in the recognition of inflammatory conditions. Ann Clin Biochem 1988; 25: 60-6.
42. Sachar D, Smith H, Chan S, et al. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986; 8: 647-50.
43. Crama BG, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut 1989; 30: 1236-10.
44. Giaffer MH, Tindale WB, Senior S, et al. Quantification of disease activity in Crohn's disease by computer analysis of Tc-99m hexamethyl propylene amine oxime (HMPAO) labelled leucocyte images. Gut 1993; 34: 68-74.
45. Weldon MJ, Masoomi AM, Britten AJ, et al. Quantification of inflammatory bowel disease using technetium-99m-HMPAO labelled leucocyte Single Photon Emission Computerised Tomography (SPECT). Gut 1995; 36: 243-50.
46. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91. (See Comments.)
47. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of inflammatory bowel disease. Gut 1995; 37: 260-3.
48. Jeejeebhoy RW, Coghill NF. The measurement of gastrointestinal protein loss by a new method. Gut 1961; 2: 123-30.
49. Bernier JJ, Desmazures CH, Florent Ch, et al. Diagnosis of protein losing enteropathy by gastrointestinal clearance of alpha-1 antitrypsin. Lancet 1978; ii: 763-4.
50. Florent C, L'Hirondel C, Desmazures C, et al. Intestinal clearance of alpha 1-antitrypsin. Gastroenterology 1981; 1981: 777-80.
51. Florent C, L'Hirondel C, Desmazures C, et al. Evaluation of ulcerative colitis and Crohn's disease activity by the measurement of alpha-1 antitrypsin intestinal clearance. Gastroenterol Clin Biol 1981; 5: 193-7.
52. Meyer S, Wolke A, Field SP, et al. Fecal alpha-1-antitrypsin measurement: an indicator of Crohn's disease activity. Gastroenterology 1985; 89: 13-18.
53. Crabtree JE, Juby LD, Heatley RV, et al. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut 1990; 31: 1033-6.
54. Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795-9.
55. Choudari CP, O'Mahony S, Brydon G, et al. Gut lavage protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993; 104: 1064-71.
56. Saverymuttu SH, Lavender JP, Hodgson HJ, et al. Assessment of disease activity in inflammatory bowel disease: a new approach using 111 In granulocyte scanning. BMJ Clin Res 1983; 287: 1751-3.
57. Saverymuttu SH, Peters AM, Crofton ME, et al. 111 Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26: 955-60.
58. 111In granulocyte excretion. Digestion 1986; 33: 74-9.
59. Carpani, de Kaski M, Peters AM, Knight D, et al. Indium-111 whole-body retention: a method for quantification of disease activity in inflammatory bowel disease. J Nucl Med 1992; 33: 756-62.
60. Neirinckx RD, Canning LR, Piper IM, et al. Tc-99m d,1-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987; 28: 191-202.
61. Lassen NA, Blasberg RG. Technetium-99m-d,1-HM-PAO, the development of a new class of 99mTc-labelled tracers: an overview. J Cereb Blood Flow Metab 1988; 8: S1-3.
62. Scholmerich J, Schmidt E, Schumichen C, et al. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label. Gastroenterology 1988; 95: 1287-93.
63. Lantto E, Jarvi K, Krekela I, et al. Technetium-99m hexamethyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease. Eur J Nucl Med 1992; 19: 14-18.
64. Papos M, Nagy F, Lang J, et al. Technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy in ulcerative colitis and Crohn's disease. Eur J Nucl Med 1993; 20: 766-9.
65. Vilien M, Nielsen SL, Jorgensen M, et al. Leucocyte scintigraphy to localize inflammatory activity in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1992; 27: 582-6.
66. Becker W, Schomann E, Fischbach W, et al. Comparison of 99Tcm-HMPAO and 111 In-oxine labelled granulocytes in man: first clinical results. Nucl Med Commun 1988; 9: 435-47.
67. Weldon M. 99mTc-HMPAO planar white cell scanning. Scand J Gastroenterol 1994; 29: 36-12.
68. Spinelli F, Milella M, Sara R, et al. The 99mTc-HMPAO leukocyte scan: an alternative to radiology and endoscopy in evaluating the extent and the activity of inflammatory bowel disease. J Nucl Biol Med 1991; 35: 82-7.
69. Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol 1991; 86: 460-6.
70. Brignola C, De SG, Iannone P, et al. Influence of steroid treatment's duration in patients with active Crohn's disease. Agents Actions 1992; Spec. no. C90-2.